# Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)

> **NCT01312922** · PHASE3 · COMPLETED · sponsor: **PharmaNeuroBoost N.V.** · enrollment: 555 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** PNB01 fixed dose combination of pipamperone and citalopram
- **DRUG:** Citalopram
- **DRUG:** Pipamperone

## Key facts

- **NCT ID:** NCT01312922
- **Lead sponsor:** PharmaNeuroBoost N.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2012-11
- **Final completion:** 2012-12
- **Target enrollment:** 555 (ACTUAL)
- **Last updated:** 2022-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01312922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01312922, "Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01312922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*